Low viscosity liquid polymeric delivery system
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C08G-063/08
A61F-002/00
A61K-009/22
출원번호
US-0812670
(2009-01-13)
등록번호
US-8187640
(2012-05-29)
국제출원번호
PCT/US2009/030853
(2009-01-13)
§371/§102 date
20101019
(20101019)
국제공개번호
WO2009/091737
(2009-07-23)
발명자
/ 주소
Dunn, Richard L.
출원인 / 주소
Dunn Research & Consulting, LLC
대리인 / 주소
Whyte Hirschboeck Dudek S.C.
인용정보
피인용 횟수 :
13인용 특허 :
108
초록
Low viscosity biodegradable polymer solutions of a liquid biodegradable polymer and biocompatible solvent and methods of using the compositions to form a biodegradable liquid polymer implant are provided.
대표청구항▼
1. A liquid polymer composition formulated for administering into a body of an animal or human, comprising: (a) a biodegradable liquid polymer comprising a copolymer of lactide and caprolactone with a molar ratio from 75/25 to 25/75 and a molecular weight of 2000 daltons to 20,000 daltons, the molec
1. A liquid polymer composition formulated for administering into a body of an animal or human, comprising: (a) a biodegradable liquid polymer comprising a copolymer of lactide and caprolactone with a molar ratio from 75/25 to 25/75 and a molecular weight of 2000 daltons to 20,000 daltons, the molecular weight as determined by gel permeation chromatography using a multi-angle light-scattering detector (GPC-MALS);(b) a biocompatible organic solvent; and(c) a therapeutically effective amount of a biologically active agent;wherein the composition, when placed in contact with body fluid of an animal or human, remains in a liquid form and does not form a solid in situ after dissipation of the organic solvent from the composition into said body fluid. 2. The composition of claim 1, wherein the solvent comprises a hydrophilic organic solvent having a water solubility greater than 10% by weight of said solvent in water. 3. The composition of claim 1, wherein the solvent comprises a hydrophilic organic solvent selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, N-ethyl-2-pyrrolidone, N-cyclohexyl-2-pyrrolidone, N-hydroxethyl-2-pyrrolidone, dimethyl acetamide, dimethyl formamide, acetic acid, lactic acid, ethanol, propanol, methyl lactate, ethyl lactate, methyl acetate, diethylene glycol monomethyl ether, glycofurol, glycerol formal, isopropylidene glycerol, dimethyl sulfoxide, ε-caprolactone, butyrolactone, propylene glycol, polyethylene glycol, glycerol, 1,3-butyleneglycol, methoxypolyethylene glycol, methoxypropylene glycol, acetone, methyl ethyl ketone, tetrahydrofuran, and combinations thereof. 4. The composition of claim 1, wherein the solvent comprises a hydrophilic organic solvent selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, ethyl lactate, glycofurol, glycerol formal, isopropylidene glycerol, propylene glycol, polyethylene glycol, methoxypolyethylene glycol, methoxypropylene glycol, and combinations thereof. 5. The composition of claim 1, wherein the solvent comprises a lipophilic organic solvent having a water solubility less than 10% by weight of the solvent in water. 6. The composition of claim 1, wherein the solvent comprises a lipophilic organic solvent selected from the group consisting of ethyl acetate, ethyl butyrate, ethyl oleate, isopropyl palmitate, ethyl palmitate, methyl palmitate, isopropyl myristate, diethyl malonate, diethyl succinate, dimethyl adipate, dimethyl succinate, dibutyl sebacate, triacetin, triethyl citrate, tributyrin, acetyl triethyl citrate, acetyl tributyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, tributyl citrate, caprylic/capric triglycerides, caprylic/capric/linoleic triglyceride, caprylic/capric/succinic triglyceride, propylene glycol dicaprylate/caprate, benzyl alcohol, ethyl benzoate, benzyl benzoate, propylene carbonate, dimethyl carbonate, N,N-diethyl-toluamide, N-dodecyl-2-pyrrolidone, N-octyl-2-pyrrolidone, N-methyl-2-caprolactam, N-dodecyl-caprolactam, heptanoic acid, oleic acid, sesame oil, peanut oil, castor oil, and combinations thereof. 7. The composition of claim 1, wherein the solvent comprises a lipophilic organic solvent selected from the group consisting of ethyl acetate, ethyl oleate, isopropyl myristate, triacetin, triethyl citrate, acetyl tributyl citrate, ethyl benzoate, benzyl benzoate, sesame oil, and combinations thereof. 8. The composition of claim 1, wherein the solvent comprises a combination of a hydrophilic solvent and a lipophilic solvent. 9. The composition of claim 1, wherein the biodegradable liquid polymer is pharmaceutically-acceptable. 10. The composition of claim 1, wherein the organic solvent is dissolvable or dispersible in situ in a body fluid of an animal or human. 11. The composition of claim 1, wherein the composition when placed in a body of an animal or human, forms a biodegradable polymeric implant having a liquid consistency. 12. The composition of claim 1, comprising 30-90% by weight liquid polymer and 10-70% by weight organic solvent, the % by weight based on the total weight of the composition. 13. The composition of claim 1, comprising 0.1-30% by weight active agent. 14. The composition of claim 1, wherein the biologically active agent is selected from the group consisting of cisplatin, carboplatin, anastozole, fulvestrant, exemestane, estradiol, testosterone, misoprostol, follicle-stimulating hormone, dustasteride, doxycycline, ciprofloxacin, quinolone, ivermectin, haloperidol, diazepam, risperidone, olanzapine, naltrexone, fentanyl, buprenorphine, butorphanol, loperamide, nafarelin, buserelin, histrelin, deslorelin, leuprolide, goserelin, triptorelin, ganirelix, abarelix, cetrorelix, teverelix, octreotide, lanreotide, human growth hormone, interferon-alpha, interferon-beta, interferon-gamma, interleukin, calcitonin, growth hormone releasing peptides, glucagon-like peptides, granulocyte-colony stimulating factor, nerve growth factor, platelet-derived growth factor, insulin-like growth factor, vascular endothelial growth factor, fibroblast growth factor, bone morphogenic protein, erythropoietin, and salts, complexes and prodrugs. 15. The composition of claim 1, wherein the organic solvent comprises N-methyl-2-pyrrolidone, and the biologically active agent is selected from the group consisting of cisplatin, carboplatin, buprenorphine, doxycycline, haloperidol, and triptorelin pamoate. 16. The composition of claim 1, wherein the organic solvent comprises triacetin, and the biologically active agent comprises triptorelin pamoate. 17. The composition of claim 1, wherein the copolymer of lactide and caprolactone has a molecular weight of 3,000 daltons to 12,000 daltons. 18. The composition of any of claims 1-17, wherein the biodegradable liquid polymer is a liquid at 25° C. up to 37° C. 19. The composition of any of claims 1-18, packaged for use in forming a biodegradable polymeric material or implant within a body of an animal or human. 20. The composition of any of claims 1-18, for use as a biodegradable polymeric implant to deliver the biologically active agent into a body of an animal or human. 21. Use of the composition of any of claims 1-18, in the preparation of a medicament for forming a biodegradable polymeric material or implant within a body of an animal or human to deliver the biologically active agent into the body. 22. A method of forming a biodegradable polymeric implant within a body of an animal or human, comprising: administering into the body an amount of a liquid polymer composition comprising: (a) a pharmaceutically acceptable, biodegradable liquid polymer comprising a copolymer of lactide and caprolactone with a molar ratio from 75/25 to 25/75 and a molecular weight of 2000 daltons to 20,000 daltons, the molecular weight as determined by gel permeation chromatography using a multi-angle light-scattering detector (GPC-MALS);(b) a biocompatible organic solvent that is dissolvable or dispersible in situ in a body fluid of the animal or human; and(c) a therapeutically effective amount of a biologically active agent; andallowing the solvent to dissipate into body fluids within the body to form the biodegradable polymeric material having a liquid consistency which does not form into a solid in situ;wherein the polymeric material releases the biologically active agent as the polymeric material biodegrades within the body. 23. The method of claim 22, wherein the liquid polymer composition is administered through a syringe or needle of 18-26 gauge. 24. The method of claim 22, wherein the liquid polymer composition is administered into a body tissue within the body of the animal or human to form a liquid implant. 25. The method of claim 22, wherein the implant is in the form of a film. 26. The method of claim 22, wherein the implant is in the form of a plug situated within the body tissue. 27. The method of claim 22, wherein the liquid polymer composition is administered onto a device selected from the group consisting of a catheter, a mesh, a screw, a plate, a tack, a pin, a staple, and a sponge, and the method further comprises placing the device with the composition thereon into the body of the animal or human. 28. The method of any of claims 22-27, further comprising, prior to administering the liquid polymer composition into the body of the animal or human, dissolving the biodegradable liquid polymer in the organic solvent, and adding an effective amount of the biologically active agent to the composition. 29. A kit comprising the composition of claim 1; and directions for preparation and/or administration of the liquid polymer composition to form the polymeric implant. 30. A method of forming a biodegradable polymeric implant within a body of an animal or human, comprising: administering into the body the liquid polymer composition of claim 1; andallowing the solvent to dissipate into body fluids to form the biodegradable polymeric implant having a liquid consistency which does not form into a solid in situ, wherein the biologically active agent is released from the polymeric implant into the body over an extended time period as the polymeric implant biodegrades.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (108)
Shalaby Shalaby W. (Long Valley NJ) Jamiolkowski Dennis D. (Paterson NJ), Absorbable pharmaceutical compositions based on poly(alkylene oxalates).
Dunn Richard L. (Birmingham AL) Gibson John W. (Kingsport TN) Eddy Carlton A. (San Antonio TX) Laufe Leonard E. (San Antonio TX), Antithrombotic/thrombolytic suture and methods of making and using the same.
Polson Alan M. (Fort Collins CO) Swanbom Deryl D. (Fort Collins CO) Dunn Richard L. (Fort Collins CO) Cox Charles P. (Fort Collins CO) Norton Richard L. (Fort Collins CO) Lowe Bryan K. (Fort Collins , Apparatus for forming a biodegradable implant precursor.
Tipton Arthur J. (Birmingham AL) Fujita Shawn M. (Amsterdam NLX) Dunn Richard L. (Fort Collins CO), Biodegradable film dressing and method for its formation.
Alan M. Polson ; Deryl D. Swanbom ; Richard L. Dunn ; Charles P. Cox ; Richard L. Norton ; Bryan K. Lowe ; Kenneth S. Peterson, Biodegradable implant precursor.
Polson Alan M. (Fort Collins CO) Swanbom Deryl D. (Fort Collins CO) Dunn Richard L. (Fort Collins CO) Cox Charles P. (Fort Collins CO) Norton Richard L. (Fort Collins CO) Lowe Bryan K. (Fort Collins , Biodegradable implant precursor.
Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Vanderbilt David D. (Birmingham AL), Biodegradable in-situ forming implants and methods for producing the same.
Dunn Richard L. (451 Boardwalk Dr. RLD ; Apt. 501 Fort Collins CO 80526) English James P. (2500 Melinda Cir. Birmingham AL 35214) Cowsar Donald R. (4657 Round Forest Dr. Birmingham AL 35213) Vanderbi, Biodegradable in-situ forming implants and methods of producing the same.
Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Vanderbilt David D. (Birmingham AL), Biodegradable in-situ forming implants and methods of producing the same.
Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Vanderbilt David P. (Birmingham AL), Biodegradable in-situ forming implants and methods of producing the same.
Vanderbilt David P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL), Biodegradable polyamides.
Vanderbilt David P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Dunn Richard L. (Collins CO) English James P. (Birmingham AL), Biodegradable polyamides for providing a controlled release therapeutic drug.
Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO) Southard George L. (Fort Collins CO) Rogers Jack A. (Fort Collins CO), Biodegradable polymer composition.
Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO) Southard George L. (Fort Collins CO) Rogers Jack A. (Fort Collins CO), Biodegradable polymer composition.
Bays F. Barry (Seminole FL) Dunn Richard L. (Birmingham AL) Marchand Sam (Olive Branch MS) Treharne ; III Richard W. (Memphis TN), Biodegradable prosthetic device.
Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO) Southard George L. (Fort Collins CO) Rogers Jack A. (Fort Collins CO), Biodegradable system for regenerating the periodontium.
Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO) Southard George L. (Fort Collins CO) Rogers Jack A. (Fort Collins CO), Biodegradable system for regenerating the periodontium.
Langer Robert S. (Somerville MA) Rosen Howard (Montara CA) Linhardt Robert J. (Iowa City IA) Leong Kam (Cambridge MA), Bioerodible polyanhydrides for controlled drug delivery.
Chandrashekar Bhagya L. ; Zhou Mingxing ; Jarr Eileen M. ; Dunn Richard L., Controlled release liquid delivery compositions with low initial drug burst.
Arenberg, Irving K.; Arenberg, Michael H.; Lemke, Christine; Berglund, John A., Controlled release system for delivering therapeutic agents into the inner ear.
Swanbom, Deryl D.; Dunn, Richard L.; Botz, Michelle; Godowski, Kenneth C.; Jeffers, Scott, Filamentous porous films and methods for producing the same.
John W. Gibson ; Stacey A. Sullivan ; John C. Middleton ; Arthur J. Tipton, High viscosity liquid controlled delivery system and medical or surgical device.
Johnson, Randolph Mellus; Theeuwes, Felix; Gillis, Edward M.; Litmanovitz, Dana; Laidlaw, Barbara; Brown, James; Culwell, John; Filice, James A.; Wickman, Peter; Yum, Su-Il; Poutiatine, Andrew; Dinka, Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners.
Berggren Randall G. (Livermore CA) Enscore David J. (Saratoga CA) Marks Susan M. (San Jose CA) Osborne James L. (Mountain View CA) Wong Patrick S.-L. (Palo Alto CA) Roorda Wouter E. (Newark CA), Injectable drug delivery system and method.
Berggren Randall G. ; Enscore David J. ; Marks Susan M. ; Osborne James L. ; Wong Patrick S.-L. ; Roorda Wouter E., Injectable drug delivery system and method.
Scopelianos Angelo G. ; Arnold Steven C. ; Bezwada Rao S. ; Roller Mark B. ; Huxel Shawn T., Injectable microdipersions for soft tissue repair and augmentation.
Scopelianos Angelo G. (Whitehouse Station NJ) Arnold Steven C. (Sparta NJ) Bezwada Rao S. (Whitehouse Station NJ) Roller Mark B. (North Brunswick NJ) Huxel Shawn T. (Lakehurst NJ), Injectable microdispersions for soft tissue repair and augmentation.
Tice Thomas R. (Birmingham AL) Lewis Danny H. (Gardendale AL) Cowsar Donald R. (Birmingham AL) Beck Lee R. (Birmingham AL), Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO) Harkrader Ronald J. (Louisville CO) Rogers Jack A. (Fort Collins CO), Intragingival delivery systems for treatment of periodontal disease.
Bezwada Rao S. (Whitehouse Station NJ) Arnold Stephen C. (Franklin NJ) Shalaby Shalaby W. (Anderson SC) Williams Bernard L. (Martinsville NJ), Liquid absorbable copolymers for parenteral applications.
Bezwada Rao S. (Whitehouse Station NJ) Arnold Stephen C. (Franklin NJ) Shalaby Shalaby W. (Anderson SC) Williams Bernard L. (Martinsville NJ), Liquid absorbable copolymers for parenteral applications.
Polson Alan M. ; Swanbom Deryl D. ; Dunn Richard L. ; Cox Charles P. ; Norton Richard L. ; Lowe Bryan K. ; Peterson Kenneth S., Method and composition for treating a bone tissue defect.
English James P. (Birmingham AL) McNeely Gerald W. (Spartanburg SC) Dunn Richard L. (Birmingham AL), Method for making a biodegradable adhesive for soft living tissue.
Angelo G. Scopelianos ; Steven C. Arnold ; Rao S. Bezwada ; Mark B. Roller ; Shawn T. Huxel ; Robert J. Tannhauser, Microdispersions for coating surgical devices.
Dunn Richard L. (Fort Collins CO) Godowski Kenneth C. (Fort Collins CO) Harkrader Ronald J. (Louisville CO) Southard George L. (Fort Collins CO), Muscosal delivery systems for treatment of periodontal disease.
Schmitt Edward E. (Palo Alto CA), Pharmaceutical composition of poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having.
Dunn, Richard L.; Garrett, John Steven; Ravivarapu, Harish; Chandrashekar, Bhagya L, Polymeric delivery formulations of leuprolide with improved efficacy.
Dunn, Richard L.; Garrett, John Steven; Ravivarapu, Harish; Chandrashekar, Bhagya L., Polymeric delivery formulations of leuprolide with improved efficacy.
Kaplan Donald S. (7 White Oak La. Weston CT 06883) Muth Ross R. (97 Clearview Dr. R.D. 2 CT 06804), Polymers for injection molding of absorbable surgical devices.
Bernick, Brian A.; Cacace, Janice Louise; Persicaner, Peter H. R.; Irani, Neda; Amadio, Julia M., Natural combination hormone replacement formulations and therapies.
Bernick, Brian A.; Amadio, Julia M.; Persicaner, Peter H. R.; Irani, Neda; Cacace, Janice Louise; Thorsteinsson, Thorsteinn; Sancilio, Frederick D., Soluble estradiol capsule for vaginal insertion.
Bernick, Brian A.; Amadio, Julia M.; Persicaner, Peter H. R.; Cacace, Janice Louise; Irani, Neda; Sancilio, Frederick D., Transdermal hormone replacement therapies.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.